Enliven Therapeutics, Inc. ELVN 深 沪
交易中 08-28 11:10:12 美东时间
59.56
-0.940
-1.55%
华盛通- 最 高61.18
- 今 开60.40
- 成交量 8.33万股
- 最 低 59.00
- 昨 收 60.50
- 总市值 43.64亿
- 52周最高 62.32
- 市盈率 静 --
- 换手率 0.11%
- 52周最低 14.785
- 委 比 20.00%
- 总股本 7327.08万
- 历史最高 250.84
- 量 比 0.46
- 振 幅 3.60%
- 历史最低 3.896
- 每 手 1
- 风险率 13.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic myeloid leukemia (CML). ELVN-001 Shows Positive Phase 1 Data Enliven Therapeutics’ lea...
08-19 01:58
Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $73
Mizuho analyst Salim Syed maintains Enliven Therapeutics (NASDAQ:ELVN) with a Outperform and raises the price target from $62 to $73.
08-18 19:48
美股大行评级 | 花旗、富国下调闪迪目标价，低至1400美元；百济神州、多邻国、DoorDash、Shopify等获多家机构上调评级
今日重点评级关注：康托·菲茨杰拉德：维持EyePoint"超配"评级，目标价从47美元升至55美元；伯恩斯坦：维持Figure Technology"跑赢大市"评级，目标价从67美元升至70美元
08-07 13:41
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $67 to $80.
08-06 19:26
Enliven Therapeutics Q2 EPS $(0.49) Misses $(0.40) Estimate
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.40) by 22.5 percent. This is unchanged from the same period last year.
08-06 04:49
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $67
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $59 to $67.
07-21 20:40
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $64
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $56 to $64.
07-09 18:22
